ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1618

Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year

Anna Stein1, Caleb Anderson2 and Angelique Collamer3, 1Walter Reed National Military Medical Center, Takoma Park, MD, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Walter Reed National Military Medical Center, Silver Spring, MD

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Cost-Effectiveness

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele, HLA-B27 is known to have a strong association with ankylosing spondylitis (AS) and is present in over 90% of Caucasian AS patients. The National Capital Consortium’s (NCC) HLA-B27 testing is conducted as a polymerase chain reaction (PCR), sequence-specific oligonucleotide probe analysis. As this is a genetic test, repeating the assay multiple times for the same individual patient is of limited diagnostic utility. The intent of this project was to determine the number of repeat HLA-B27 tests that occur within the NCC during a calendar year and the approximate cost associated with this repeat testing.

Methods: A record of all HLA-B27 tests ordered in the NCC between January 1 2019 and December 31 2019 was obtained. Chart reviews were performed to identify whether these patients had prior HLA-B27 testing conducted over the lifetime of the patient in the electronic medical record (EMR) and the number of prior tests. Ordering location of the testing (primary care, ophthalmology/optometry, rheumatology, other specialty clinic, inpatient, and outside provider) was also recorded. The cost of repeat testing was then estimated per the facility’s contract with LabCorp.

Results: Between January 1 2019 and December 31 2019, 460 HLA-B27 tests were conducted for patients within the NCC. Of these, 33 (7%) represented repeat tests associated with a cost of approximately 5,610 dollars. Five of the thirty-two HLA-B27 tests ordered by outside providers (16%) represented repeat studies associated with a cost of approximately 850 dollars. The specialty with the second highest percentage of repeat tests was ophthalmology and optometry (8 repeat tests, 13% of all tests ordered by the specialty, $1,360 spent in repeat tests), followed by pediatric rheumatology (5, 11%, $850), other specialty clinics (6, 5%, $1,020), primary care (7, 5%, $1,190), and adult rheumatology (2, 5%, $340).

Conclusion: In this review of ordering practices, repeat HLA-B27 testing accounted for 7% of tests ordered in the NCC over one calendar year. While the majority of HLA-B27 tests were ordered in the primary care setting, the highest rates of repeat testing were conducted by outside providers, ophthalmology/optometry, and pediatric rheumatology. This repeat testing is not insignificant; when extrapolated it represents an estimated ten year cost of over $56,000 to our facility. We hypothesize that lack of access to our facility’s EMR, use of order sets, and insufficient time to review the EMR represent major factors contributing to repeat HLA-B27 testing. Our findings suggest that efforts to reduce HLA-B27’s inclusion in order sets and introduction of EMR “flags” to prevent repeat ordering may reflect reasonable interventions to lower repeat testing within our system.


Disclosure: A. Stein, None; C. Anderson, None; A. Collamer, None.

To cite this abstract in AMA style:

Stein A, Anderson C, Collamer A. Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/frequency-and-cost-of-repeat-hla-b27-testing-within-the-national-capital-consortium-over-a-calendar-year/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-and-cost-of-repeat-hla-b27-testing-within-the-national-capital-consortium-over-a-calendar-year/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology